Children, Vol. 10, Pages 863: Pediatric COVID-TB: A Clinical Perspective Based on the Analysis of Three Cases

1 year ago 31

Children, Vol. 10, Pages 863: Pediatric COVID-TB: A Clinical Perspective Based on the Analysis of Three Cases

Children doi: 10.3390/children10050863

Authors: Fabrizio Leone Martina Di Giuseppe Maia De Luca Laura Cursi Francesca Ippolita Calo Carducci Andrzej Krzysztofiak Sara Chiurchiù Lorenza Romani Cristina Russo Laura Lancella Stefania Bernardi

Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are currently two major causes of death among infectious diseases. Active tuberculosis and a history of tuberculosis appear to be associated with an increased risk of COVID-19. This coinfection, named COVID-TB, was never described in previously healthy children. We report three cases of pediatric COVID-TB. We describe three girls affected by tuberculosis, who tested positive for SARS-CoV-2. The first patient is a 5-year-old girl who was hospitalized for recurrent TB lymphadenopathy. As she never had any complications related to the concomitant infection with SARS-CoV-2, she received TB treatment. The second case is a 13-year-old patient with a history of pulmonary and splenic tuberculosis. She was admitted to the hospital due to deteriorating respiratory dynamics. She was already undergoing treatment for TB, but in the absence of improvement, she also required treatment for COVID-19. Slowly, the general condition improved until discharge. The last patient, a 10-year-old girl, was hospitalized for supraclavicular swelling. The investigations showed disseminated TB characterized by lung and bone involvement without COVID-19-related complications. She was treated with antitubercular and supportive therapy. Based on the data obtained from the adult population and our small experience, a pediatric patient with COVID-TB infection should be considered potentially at risk of worse clinical outcomes; for this reason, we suggest close observation, careful clinical management, and consideration of targeted anti-SARS-CoV-2 therapies.

Read Entire Article